{"title":"New-onset Bipolar Disorder in Hidradenitis Suppurativa Patients: A Multi-center, Propensity-score-matched Cohort Study.","authors":"Meng-Che Wu, Yun-Feng Li, Chen-Yu Lin, Nung-Hsiang Lin, Chien-Ying Lee, Yu-Jung Su, Hui-Chin Chang, Shuo-Yan Gau","doi":"10.21873/invivo.13911","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Hidradenitis suppurativa (HS) may be linked to an elevated risk of bipolar disorder, though the precise mechanism remains unclear. This study investigated the likelihood of bipolar disorder in patients with HS.</p><p><strong>Patients and methods: </strong>We analyzed the electronic health records of 60,850 patients with HS and 60,850 matched controls from the TriNetX network, excluding those with a prior bipolar disorder diagnosis. Propensity score matching was conducted (1:1 ratio), and hazard ratios (HRs) were calculated to assess the risk of new-onset bipolar disorder in patients with HS compared to controls.</p><p><strong>Results: </strong>After matching, the HR for developing bipolar disorder in patients with HS was 1.549 [95% confidence interval (CI)=1.270-1.889] after a 1-year follow-up, remaining significant in 3- and 5-year follow-ups and sensitivity analyses. Stratified by sex, female patients with HS showed a notably higher risk (HR=1.509, 95%CI=1.353-1.683), while no significant increase was seen in males.</p><p><strong>Conclusion: </strong>Patients with HS have a significantly elevated risk of developing bipolar disorder, especially among females. Healthcare providers should be mindful of this association when treating patients with HS.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 2","pages":"1067-1077"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884441/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13911","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Hidradenitis suppurativa (HS) may be linked to an elevated risk of bipolar disorder, though the precise mechanism remains unclear. This study investigated the likelihood of bipolar disorder in patients with HS.
Patients and methods: We analyzed the electronic health records of 60,850 patients with HS and 60,850 matched controls from the TriNetX network, excluding those with a prior bipolar disorder diagnosis. Propensity score matching was conducted (1:1 ratio), and hazard ratios (HRs) were calculated to assess the risk of new-onset bipolar disorder in patients with HS compared to controls.
Results: After matching, the HR for developing bipolar disorder in patients with HS was 1.549 [95% confidence interval (CI)=1.270-1.889] after a 1-year follow-up, remaining significant in 3- and 5-year follow-ups and sensitivity analyses. Stratified by sex, female patients with HS showed a notably higher risk (HR=1.509, 95%CI=1.353-1.683), while no significant increase was seen in males.
Conclusion: Patients with HS have a significantly elevated risk of developing bipolar disorder, especially among females. Healthcare providers should be mindful of this association when treating patients with HS.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.